TapewireFind a company

person · Reporting owner

Lundbeckfond Invest A/S

Disclosed activity across 6 companies

Tapewire entity
108415
SEC CIK
0001591046

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
IO Biotech, Inc.IOBT · Entity 8764Director · 10% ownerAugust 09, 2023August 12, 2023
Spero Therapeutics, Inc.SPRO · Entity 701410% ownerNovember 01, 2017November 01, 2017
scPharmaceuticals Inc.SCPH · Entity 7445610% ownerNovember 21, 2017November 21, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IO Biotech, Inc.

Report date August 09, 2023 · Filed August 12, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect13,950,686 Reported balance After 2023-08-09 transaction · row 1
1 source row

Row 1 · 2023-08-09 · Grant · Acquired 7,901,234 · Balance 13,950,686

Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47Direct7,901,234 Reported balance After 2023-08-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2023-08-09 · Grant · Acquired 7,901,234 · Balance 7,901,234

F1: These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023).

Filing footnotes · ownership attribution and instrument terms

F1: These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023).

Spero Therapeutics, Inc.

Report date November 01, 2017 · Filed November 01, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Series A Preferred StockSEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2017-11-01 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: The shares of Series A preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2: Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017.

Series B Preferred StockSEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2017-11-01 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance Not disclosed

F3: The shares of Series B preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2: Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017.

Series C Preferred StockSEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2017-11-01 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance Not disclosed

F4: The shares of Series C preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2: Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Series A preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2: Share numbers give effect to the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017.

F3: The shares of Series B preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4: The shares of Series C preferred stock are convertible into the number of shares of common stock shown in Column 3, calculated using the conversion ratio set forth in the Issuer's Amended and Restated Certificate of Incorporation, as amended, at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

scPharmaceuticals Inc.

Report date November 21, 2017 · Filed November 21, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,183,986 Ending reported balance After 2017-11-21 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2017-11-21 · Conversion · Acquired 1,544,858 · Balance 1,544,858

F1: Represents the total number of shares of Common Stock received by the Reporting Person upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

Row 2 · 2017-11-21 · Conversion · Acquired 984,366 · Balance 2,529,224

F2: Represents the total number of shares of Common Stock received by the Reporting Person upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

Row 3 · 2017-11-21 · Purchase · Acquired 654,762 · Balance 3,183,986

Series A Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2017-11-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2017-11-21 · Conversion · Disposed 11,092,383 · Balance 0

F3: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date.

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2017-11-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2017-11-21 · Conversion · Disposed 7,067,945 · Balance 0

F3: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the total number of shares of Common Stock received by the Reporting Person upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2: Represents the total number of shares of Common Stock received by the Reporting Person upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F3: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Enliven Therapeutics, Inc.

Report date March 16, 2020 · Filed March 16, 2020

Section 16 reporting ended · disclosed 2020-03-16. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,432,722 Ending reported balance After 2020-03-16 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2020-03-16 · Conversion · Acquired 1,245,222 · Balance 1,245,222

F1: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Row 2 · 2020-03-16 · Purchase · Acquired 187,500 · Balance 1,432,722

Series Seed Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-03-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2020-03-16 · Conversion · Disposed 478,749 · Balance 0

F1: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Series A Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-03-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2020-03-16 · Conversion · Disposed 5,470,492 · Balance 0

F2: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-03-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2020-03-16 · Conversion · Disposed 1,894,444 · Balance 0

F3: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Lexeo Therapeutics, Inc.

Report date November 07, 2023 · Filed November 10, 2023

Section 16 reporting ended · disclosed 2023-11-10. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,835,959 Ending reported balance After 2023-11-07 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2023-11-07 · Conversion · Acquired 1,321,474 · Balance 1,321,474

F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

Row 2 · 2023-11-07 · Conversion · Acquired 287,213 · Balance 1,608,687

F2: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Row 3 · 2023-11-07 · Purchase · Acquired 227,272 · Balance 1,835,959

Series A convertible preferred stockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2023-11-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2023-11-07 · Conversion · Disposed 13,999,999 · Balance 0

F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

Series B convertible preferred stockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2023-11-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2023-11-07 · Conversion · Disposed 2,615,533 · Balance 0

F2: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

F2: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Trevi Therapeutics, Inc.

Report date May 09, 2019 · Filed May 13, 2019

Section 16 reporting ended · disclosed 2019-05-13. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,151,544 Ending reported balance After 2019-05-09 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2019-05-09 · Conversion · Acquired 776,544 · Balance 776,544

F1: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Row 2 · 2019-05-09 · Purchase · Acquired 375,000 · Balance 1,151,544

Series C Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2019-05-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2019-05-09 · Conversion · Disposed 6,849,315 · Balance 0

F1: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 07, 2023 Filed Nov 10, 2023 01:33 UTC Lexeo Therapeutics, Inc. LXEO · Entity 5687 ConversionSeries B convertible preferred stock · Derivative 2,615,533 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-054907 · doc4.xml · derivative · entry 5

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 287,213 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

F2 · price: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

F2 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

F2 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Read SEC document
November 07, 2023 Filed Nov 10, 2023 01:33 UTC Lexeo Therapeutics, Inc. LXEO · Entity 5687 ConversionSeries A convertible preferred stock · Derivative 13,999,999 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-054907 · doc4.xml · derivative · entry 4

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,321,474 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

Read SEC document
November 07, 2023 Filed Nov 10, 2023 01:33 UTC Lexeo Therapeutics, Inc. LXEO · Entity 5687 PurchaseCommon Stock 227,272 $11.00 $2,499,992.00
Disclosure

SEC source: 0001209191-23-054907 · doc4.xml · nonDerivative · entry 3

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,835,959

Read SEC document
November 07, 2023 Filed Nov 10, 2023 01:33 UTC Lexeo Therapeutics, Inc. LXEO · Entity 5687 ConversionCommon Stock 287,213 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-054907 · doc4.xml · nonDerivative · entry 2

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,608,687

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Read SEC document
November 07, 2023 Filed Nov 10, 2023 01:33 UTC Lexeo Therapeutics, Inc. LXEO · Entity 5687 ConversionCommon Stock 1,321,474 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-054907 · doc4.xml · nonDerivative · entry 1

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,321,474

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

Read SEC document
August 09, 2023 Filed Aug 12, 2023 01:22 UTC IO Biotech, Inc. IOBT · Entity 8764 GrantWarrants (Right to Buy) · Derivative 7,901,234 $0.13 Strike: $2.47 $987,654.25
Disclosure

SEC source: 0001140361-23-039344 · form4.xml · derivative · entry 2

Lundbeckfond Invest A/S · CIK 0001591046 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,901,234

Underlying: Common Stock · 7,901,234 shares

Expires not disclosed

F1 · derivative.expiration_date: These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023).

Read SEC document
August 09, 2023 Filed Aug 12, 2023 01:22 UTC IO Biotech, Inc. IOBT · Entity 8764 GrantCommon Stock 7,901,234 $1.90 $15,012,344.60
Disclosure

SEC source: 0001140361-23-039344 · form4.xml · nonDerivative · entry 1

Lundbeckfond Invest A/S · CIK 0001591046 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,950,686

Read SEC document
November 09, 2021 Filed Nov 12, 2021 21:15 UTC IO Biotech, Inc. IOBT · Entity 8764 ConversionSeries C Preferred Stock · Derivative 150,534 $0.00 $0.00
Disclosure

SEC source: 0001140361-21-037653 · form4.xml · derivative · entry 5

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,892,434 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.

Read SEC document
November 09, 2021 Filed Nov 12, 2021 21:15 UTC IO Biotech, Inc. IOBT · Entity 8764 ConversionSeries B Preferred Stock · Derivative 219,595 $0.00 $0.00
Disclosure

SEC source: 0001140361-21-037653 · form4.xml · derivative · entry 4

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,014,161 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date.

Read SEC document
November 09, 2021 Filed Nov 12, 2021 21:15 UTC IO Biotech, Inc. IOBT · Entity 8764 PurchaseCommon Stock 2,142,857 $14.00 $29,999,998.00
Disclosure

SEC source: 0001140361-21-037653 · form4.xml · nonDerivative · entry 3

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,049,452

Read SEC document
November 09, 2021 Filed Nov 12, 2021 21:15 UTC IO Biotech, Inc. IOBT · Entity 8764 ConversionCommon Stock 1,892,434 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-21-037653 · form4.xml · nonDerivative · entry 2

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,906,595

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.

Read SEC document
November 09, 2021 Filed Nov 12, 2021 21:15 UTC IO Biotech, Inc. IOBT · Entity 8764 ConversionCommon Stock 2,014,161 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-21-037653 · form4.xml · nonDerivative · entry 1

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,014,161

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date.

Read SEC document
March 16, 2020 Filed Mar 16, 2020 21:07 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 ConversionSeries B Preferred Stock · Derivative 1,894,444 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-008479 · doc4.xml · derivative · entry 5

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 300,752 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · derivative.exercise_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · derivative.expiration_date: On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Read SEC document
March 16, 2020 Filed Mar 16, 2020 21:07 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 ConversionSeries A Preferred Stock · Derivative 5,470,492 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-008479 · doc4.xml · derivative · entry 4

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 868,467 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · derivative.exercise_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · derivative.expiration_date: On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Read SEC document
March 16, 2020 Filed Mar 16, 2020 21:07 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 ConversionSeries Seed Preferred Stock · Derivative 478,749 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-008479 · doc4.xml · derivative · entry 3

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 76,003 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.exercise_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.expiration_date: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Read SEC document
March 16, 2020 Filed Mar 16, 2020 21:07 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 PurchaseCommon Stock 187,500 $16.00 $3,000,000.00
Disclosure

SEC source: 0000899243-20-008479 · doc4.xml · nonDerivative · entry 2

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,432,722

Read SEC document
March 16, 2020 Filed Mar 16, 2020 21:07 UTC Enliven Therapeutics, Inc. IMRA · Entity 4024 ConversionCommon Stock 1,245,222 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-008479 · doc4.xml · nonDerivative · entry 1

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,245,222

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Read SEC document
May 09, 2019 Filed May 13, 2019 21:00 UTC Trevi Therapeutics, Inc. TRVI · Entity 4387 ConversionSeries C Preferred Stock · Derivative 6,849,315 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-013250 · doc4.xml · derivative · entry 3

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 776,544 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.exercise_date: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.expiration_date: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Read SEC document
May 09, 2019 Filed May 13, 2019 21:00 UTC Trevi Therapeutics, Inc. TRVI · Entity 4387 PurchaseCommon Stock 375,000 $10.00 $3,750,000.00
Disclosure

SEC source: 0000899243-19-013250 · doc4.xml · nonDerivative · entry 2

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,151,544

Read SEC document
May 09, 2019 Filed May 13, 2019 21:00 UTC Trevi Therapeutics, Inc. TRVI · Entity 4387 ConversionCommon Stock 776,544 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-013250 · doc4.xml · nonDerivative · entry 1

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 776,544

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Read SEC document
November 21, 2017 Filed Nov 21, 2017 19:24 UTC scPharmaceuticals Inc. SCPH · Entity 74456 ConversionSeries B Preferred Stock · Derivative 7,067,945 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-027197 · doc4.xml · derivative · entry 5

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 984,366 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date.

F3 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date.

F3 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date.

F3 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date.

Read SEC document
November 21, 2017 Filed Nov 21, 2017 19:24 UTC scPharmaceuticals Inc. SCPH · Entity 74456 ConversionSeries A Preferred Stock · Derivative 11,092,383 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-027197 · doc4.xml · derivative · entry 4

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,544,858 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date.

F3 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date.

F3 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date.

F3 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis upon on November 21, 2017 and had no expiration date.

Read SEC document
November 21, 2017 Filed Nov 21, 2017 19:24 UTC scPharmaceuticals Inc. SCPH · Entity 74456 PurchaseCommon Stock 654,762 $14.00 $9,166,668.00
Disclosure

SEC source: 0000899243-17-027197 · doc4.xml · nonDerivative · entry 3

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,183,986

Read SEC document
November 21, 2017 Filed Nov 21, 2017 19:24 UTC scPharmaceuticals Inc. SCPH · Entity 74456 ConversionCommon Stock 984,366 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-027197 · doc4.xml · nonDerivative · entry 2

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,529,224

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Represents the total number of shares of Common Stock received by the Reporting Person upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

Read SEC document
November 21, 2017 Filed Nov 21, 2017 19:24 UTC scPharmaceuticals Inc. SCPH · Entity 74456 ConversionCommon Stock 1,544,858 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-027197 · doc4.xml · nonDerivative · entry 1

Lundbeckfond Invest A/S · CIK 0001591046 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,544,858

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the total number of shares of Common Stock received by the Reporting Person upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.